Why Taro Pharmaceutical Is Poised to Keep Popping

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical products company Taro Pharmaceutical Industries (NYSE: TARO  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Taro and see what CAPS investors are saying about the stock right now.

Taro facts

Headquarters (founded)

Haifa Bay, Israel (1959)

Market Cap

$2.4 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$688.4 million

Management

Interim CEO James Kedrowski
Interim CFO Michael Kalb

Trailing-12-Month Operating Margin

53.8%

Cash/Debt

$479.1 million / $28.3 million

Competitors

Perrigo
Sandoz International
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 92% of the 50 members who have rated Taro believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star DrGoldin, succinctly summed up the Taro bull case for our community: "What's not to like? Margins and returns at the high end of the industry, with nothing but consistent growth for the future. All this at a modest p/e (however you wish to calculate it). And clean sheets!"

If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its four-star rating, Taro may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2255725, ~/Articles/ArticleHandler.aspx, 7/24/2014 9:55:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement